Compare Cytokinetics Inc (CYTK) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Huntington Bancshares Incorporated — how do they compare? Cytokinetics Inc trades at $62.69 (market cap $8.62B), while Huntington Bancshares Incorporated trades at $15.31 (market cap $31.04B). The key difference: Huntington Bancshares Incorporated is far larger — about 3.6× Cytokinetics Inc's market cap, and Huntington Bancshares Incorporated pays a 4.04% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Huntington Bancshares Incorporated for 52 Days on average.
| CYTK | HBAN | |
|---|---|---|
Market Cap | $8.62B | $31.04B |
Volume | 2,594,626 | 23,864,172 |
Sector | Health | Financials |
52-Week High | $87.26 | $19.27 |
52-Week Low | $54.76 | $15.02 |
Typical Hold Time | 19 Days | 52 Days |
Enterprise Value | $8.72B | $49.57B |
Dividend Yield | — | 4.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
Huntington Bancshares (HBAN) trades at $15.32, up 0.99% on the day, with a bearish technical signal and mixed earnings history. The company reported 2025 revenue of $8.13B and net income of $2.21B, with a P/E of 11.82 and ROE of 9.23%. Recent news highlights an increased prime rate to 7.00% and a revised 2027 earnings outlook due to margin pressures.
Outlook is cautious; analyst consensus is a Buy with a $19.60 price target, but near-term headwinds from higher interest rates and deposit costs pose risks. The stock offers value based on valuation metrics, yet investors should weigh margin pressures against shareholder return initiatives like the $550M buyback plan for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
